Published in final edited form as:

Biol Psychiatry. 2009 October 1; 66(7): 636–641. doi:10.1016/j.biopsych.2009.04.017.

DCS facilitation of fear extinction and exposure-based therapy may rely on lower-level, automatic mechanisms

Christian Grillon, PhD

Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA

Abstract

Exposure-based therapy (EBT), a leading technique in the treatment of a range of anxiety disorders, is facilitated by D-cycloserine (DCS), a partial N-methyl-D-aspartate (NMDA) receptor agonist. This review discusses the potential mechanisms involved in this facilitation, and its implications for developing theories of fear conditioning in humans. Basic research in rodents suggests that DCS acts by speeding up extinction. However, several lab-based investigations found that DCS had no effect on extinction in humans. This paper proposes that these observations can be accounted for by a dual-model theory of fear conditioning in humans that engages two complementary defensive systems: a reflexive lower-order system independent of conscious awareness and a higher-order cognitive system associated with conscious awareness of danger and expectation. DCS studies in animals appear to have explored lower-order conditioning mechanisms, whereas human studies have explored higher-order cognitive processes. These observations suggest that DCS may act preferentially on lower- rather than higher-order learning. This paper presents evidence suggesting that, in humans, DCS may similarly affect lower-order learning during EBT and, consequently, may be less effective during cognitive therapy (e.g., cognitive restructuring). Finally, it is recommended that extinction studies using DCS in humans be conducted using fear-relevant stimuli (e.g., snakes), short conditional stimulus-unconditioned stimulus (CS-US) intervals, and intense US in order to promote lower-order conditioning processes.

Keywords

D-cycloserine (DCS); fear conditioning; extinction; exposure-based therapy; anxiety disorders; phobia

Introduction

The finding that D-cycloserine (DCS), a partial N-methyl-D-aspartate (NMDA) receptor agonist, enhances exposure-based therapy (EBT) for height phobia generated considerable excitement for its use as a novel treatment strategy for anxiety disorders (1). While traditional anxiolytics such as the benzodiazepines or selective serotonin reuptake inhibitors reduce symptom expression, DCS facilitates the effectiveness of EBT (1-5).

Send reprint requests to: Christian Grillon, Ph.D., NIMH/MAP, 15K North Drive, Bldg 15K, Room 113, MSC 2670, Bethesda, MD 20892-2670, Phone: (301) 594 2894, Fax: (301) 594 9959, Christian.grillon@nih.gov.

DISCLOSURE/CONFLICT OF INTEREST The author declares that, except for income received from the primary employer, no financial support or compensation has been received from any individual or corporate entity over the past three years for research or professional service and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest.

The strategy of combining EBT with DCS is based on two assumptions. First, basic research in rodents shows that DCS facilitates extinction, defined as the decrease in conditioned fear that occurs following the repeated presentation of a conditioned stimulus (CS) in the absence of an aversive unconditioned stimulus (US) with which it had been initially paired. Second, EBT, which consists of confronting patients with the feared stimulus without adverse consequences, relies on extinction principles (1,6). Thus, DCS facilitates the extinction learning that takes place during EBT (7-9). However, DCS has no effect on lab-based extinction in humans (see below), raising questions regarding the precise nature of the learning process via which this agent operates.

As this review will discuss, the contradictory findings regarding DCS's effectiveness in extinction studies can in fact be used to refine our thinking of how fear conditioning and EBT operate in humans. Based on these disparities, this review presents evidence of a dual-model theory of fear conditioning in humans that can engage two complementary defensive systems: a basic, lower-order, automatic process independent of conscious awareness, and a higher-order cognitive system associated with conscious awareness of danger and anticipation (10, 11). Evidence suggests that conditioning in rodents is essentially a low-level, automatic process (12), whereas lab-based conditioning in humans relies essentially on high-level cognitive learning (13,14). The fact that DCS influences extinction in rodents but not in humans suggests that DCS may act preferentially on lower- rather than higher-order learning. If so, DCS may similarly affect lower-order learning during EBT. Support for these hypotheses and implications for our understanding of the effects of DCS on the psychological treatment of anxiety disorders are discussed below.

Fear conditioning

Fear conditioning has long been a cross-species model paradigm to study the learning and unlearning of fear. During fear conditioning, a CS is repeatedly paired with an aversive US. Subsequent presentation of the CS can evoke a conditioned fear response (CR), which progressively extinguishes when the CS is no longer reinforced with the US. Most of our knowledge regarding conditioning mechanisms is based on rodent studies, raising the question of the generalizability of findings to humans. Of special relevance is the role of lower-order subcortical automatic mechanisms as opposed to higher-order cognitive processes, which dominate in humans (13,14).

Fear conditioning in animals

In vertebrates, phylogenetically older neural structures detect and react rapidly and reflexively to danger cues (e.g., the CS). The amygdala plays a pivotal role in all aspects of fear conditioning (15). Detection and response to a CS can be learned and expressed in the absence of a cortex (16), suggesting low-level processing (17). Indeed, CRs in rodents can be mediated by a lower-level thalamo-amygdala pathway that provides a crude but rapid analysis of stimuli (17,18).

The amygdala is also the central neural node of response expression, facilitating and synchronizing rapid reactions to danger. Efferents from the central nucleus of the amygdala to the hypothalamus and various brainstem sites enable a rapid and integrated defensive response. These connections are hard-wired so that warning cues can automatically activate the fight and flight response (19). This bottom-up mechanism facilitates automatic fear before full identification of the nature of the threat, and is advantageous for survival in the face of immediate danger. However, because it is impervious to conscious cognitive controls, it can become maladaptive, and may constitute a substrate for phobic fears (20).

Fear conditioning can also involve higher-order processes in animals. In a seminal review, Rescorla argued that conditioning involves learning the relationship between events as well as the memory representation of the US, and that it is influenced by past experience and contextual variables (21). Further, while rodents without cortices can learn a fearful response to a CS (16,18), the cortex is necessary for more elaborate learning involving complex stimuli. For example, rabbits undergoing differential conditioning procedures where only one of two tones was associated with a shock responded to both tones following lesions of the auditory cortex (22). Similarly, the hippocampus is necessary for conditioning to contextual stimuli (23,24). Thus, parallel conditioning mechanisms operate in animals; complex conditioning engages higher-order processing while simpler forms of conditioning (e.g., single cue) rely on lower-order processing. This dual mechanism is particularly relevant to our understanding of drug effects on conditioning. Because lower- and higher-order fear learning rely on different neural structures, a treatment that affects one type of conditioning would not necessarily be expected to influence the other type of conditioning. Notably, DCS studies in animals have mostly relied on single cue fear conditioning, suggesting that DCS may operate largely on lower-order processes.

A dual-model theory of fear conditioning

The extent to which animal conditioning findings apply to humans is of particular concern precisely because humans are endowed with a well-developed cognitive system capable of relational learning, defined as the controlled reasoning ability to infer relationships between events (13,20). Although modern theories view fear conditioning learning in animals in terms of associative learning and anticipatory responses (21), the nature of conditioning in rodents and in humans is quite different. Cognitive processes in rodents may be the precursors of high-order cognitive processes and language in humans, but they are not equivalent. Human subjects enter the laboratory with unique motivations and expectations likely to influence the CR. Hence, a critical issue in human research involves the degree to which the CR depends on fast, automatic, and low-level processes versus a more cognitive response that could be couched in terms of relational learning, conscious thoughts, and anticipation (11,13,14,25). Most likely, both lower-and higher-order processes are involved; a dual-model theory of fear conditioning is the simplest explanation for conditioning data in humans (10,11).

A dual-model theory of conditioning is consistent with current conceptions of human learning and memory that distinguish between implicit, lower-order mechanisms that are rapid, automatic, and inaccessible to awareness, and explicit, higher-order processes that are slow, deliberate, and conscious (12,26). An important difference between conditioning in humans and animals is that humans can report their awareness of the CS-US contingency. Several studies using various procedures demonstrate that conditioning can take place in the absence of contingency awareness (27). For instance, backward masking is a technique in which a visual test stimulus is briefly presented, then followed closely by another salient visual stimulus that 'masks' the perception of the test stimulus. Using this approach, it has been shown that CRs can be evoked by backwardly masked CS (28,29). In addition, neurological patients who cannot see the CS due to cortical blindness can exhibit a CR to a visual CS (30). Consistent with Ledoux's subcortical fear mechanism, a direct subcortical pathway to the amygdala that bypasses sensory cortices has been identified in humans (31), providing a substrate for automatic fears that arise independent of cognitive control.

In humans, conditioning can also rely on high-level cognitive factors involved in consciously learned causal relationships between events and anticipation. In fact, most studies show that CRs to non-masked CSs rely strongly on awareness of CS-US contingency (14,28,29,32,33). Proponents of the cognitive view of conditioning postulate that CRs are mediated by anticipation of, and preparation for, the US (13,14).

Both low- and high-order processes are engaged by traumatic events (10), but these can also be dissociated in humans with rare brain lesions. Explicit learning requires an intact temporal lobe (hippocampus and related cortical areas), but implicit learning can be demonstrated in patients with hippocampal damage (34). For instance, Bechara and colleagues reported that a patient with selective hippocampal damage showed no awareness of CS-US contingency but exhibited normal CR, whereas a patient with selective amygdala lesions could report the CS-US contingency, but no CR (35). In addition to using backward masking techniques, implicit learning can also be facilitated in healthy subjects via the use of fear-relevant stimuli (e.g., snake) (28), a short CS-US interval (36), or intense US (37).

Social learning: Vicarious conditioning and verbal communication

There are several mechanisms of fear learning, including fear conditioning following a direct experience with a traumatic stimulus, vicarious conditioning, and verbal information (38). Vicarious conditioning, which does not involve an encounter with an aversive stimulus, has been observed in several animal species (39-41) as well as humans (42). Verbal information, which also does not involve an encounter with an aversive stimulus, is a powerful way to acquire fears unique to humans (42). Subjects instructed to expect noxious stimuli display robust fear, even when no noxious stimuli are actually administered (43). Similarly, negative information provided by adults can greatly influence children's fear of an object with which they have no prior experience (44). Retrospective studies show that most normal and clinical fears in children are acquired through a combination of these three learning mechanisms (45).

A key question concerns the extent to which mechanisms of fear extinction differ among these different learning pathways. Differences in extinction mechanisms raise the possibility that they could be differently affected by a variety of therapeutic interventions, including DCS. There is preliminary evidence suggesting that fear and vicarious conditioning may involve automatic processes whereas verbal information may not (37,42).

Effects of DCS on extinction and EBT

Studies in rodents indicate that extinction can be blocked by NMDA antagonists via NMDA receptor-dependent neural plasticity within the basolateral amygdala (46,47). In rats, DCS, which is a partial NMDA agonist, facilitates extinction when administered just before as well as up to 60 minutes after extinction training (7-9), suggesting that DCS facilitates the consolidation of extinction learning rather than extinction learning per se (48). In addition, single dose treatments appear to be more effective than repeated treatments, perhaps because chronic treatment with DCS abolishes its activity at the NMDA receptor (49). In fact, the facilitating effect of DCS on extinction is suppressed by a single pre-exposure dose of DCS given shortly before treatment (49).

Because the efficacy of EBT is augmented by the concomitant administration of DCS, the effects of this agent on extinction facilitation are clinically useful. The first published study examined the effect of 50 mg and 500 mg DCS during two EBT sessions for height phobia (1). DCS significantly improved symptoms one week and one month post-treatment. A second study showed greater improvement in social phobics who received brief EBT combined with 50 mg DCS (2). These initial positive results were extended to the treatment of obsessive compulsive disorder (OCD) in two studies (4,5), but not in a third one (50). Overall, four of five clinical studies confirmed the efficacy of a treatment strategy combining DCS with EBT in humans.

In contrast to the positive results obtained in clinical studies of patients with a DSM-diagnosed anxiety disorder, investigations in non-clinical samples have surprisingly been unanimously negative. Two studies of individuals with non-clinical spider phobia found that 50 mg or 500

mg of DCS did not facilitate a one-session EBT when post-treatment assessment was conducted on the same day as treatment, or one month later (51). DCS's lack of same-day efficacy is consistent with animal data indicating that DCS does not facilitate extinction learning per se and requires a period of extinction consolidation; however, it cannot account for the negative effect at follow-up. This negative result was attributed to the use of a sub-clinical population with less severe symptoms, as well as the substantial efficacy of EBT, which left little room for improvement (51).

Similarly, studies of lab-based fear conditioning in healthy controls unanimously failed to show that DCS facilitates extinction. It is important to note at the outset that all these studies used conditioning procedures that tap onto higher-order cognitive processes. In the first two studies of a three-study investigation, DCS was administered between acquisition and extinction training that took place on the same day (52). DCS did not facilitate extinction when tested a day later. The negative findings were attributed to DCS influencing both acquisition and extinction. This possibility was eliminated in the third study, where DCS was given prior to extinction training conducted one day after acquisition. Again, DCS did not facilitate extinction. This finding remained in place in an analysis restricted to individuals with the best conditioning, eliminating the possibility that a floor effect masked DCS's effect.

A recent study used a complex design to examine the effect of 500 mg of DCS on conditioning (53). DCS was administered during a session that involved acquisition training in one context followed by extinction training in a different context. As noted earlier, one problem with such a design is that DCS could influence both learning processes. Results showed retention of fear conditioning in the acquisition and extinction contexts only in the DCS group during a recall test 72 hours after the acquisition/extinction session; according to the authors, this finding suggested that DCS facilitated fear acquisition (53). However, the persistence of conditioned fear in the extinction context could also be interpreted as suggesting that DCS actually impaired rather than facilitated extinction.

Basic methodological differences could explain disparities between human and animal findings. One key difference is the method used to measure conditioned fear in humans and in animals. Human studies traditionally rely on the skin conductance response (52,53), whereas rodent investigations use freezing or the startle response to assess fear. Notably, skin conductance is a rather indirect index of fear that reflects orientation to a stimulus as a function of its relevance and not necessarily its emotional significance (14,54). The negative findings in humans may thus have been due to the use of indirect measures of conditioned fear. In contrast, the startle reflex, a well-validated cross-species measure of fear conditioning (55), may be a more sensitive index of the type of conditioning that DCS influences; however, this possibility was not substantiated by two recent studies that found that DCS did not facilitate extinction as measured with the startle reflex (56,57). Both studies involved differential fear conditioning using a noxious shock as the US. Additionally, in both studies the dose of DCS (250 mg (56) or 50 mg or 500 mg (57)) was administered two hours before a short extinction training trial that took place 24 hours after acquisition; the test of extinction retention was conducted 48 hours after extinction, in order to allow consolidation of extinction learning. The negative findings obtained by these two studies are especially puzzling given that the initial finding of DCS-induced facilitation of extinction in rodents was based on fear-potentiated startle (9).

The conflicting results between human and animal conditioning studies do not appear to be caused by significant methodological differences. Most of the general procedures used in rodent investigations (i.e., DCS dose, time of administration, separate sessions for acquisition and extinction training as well as retention testing) were replicated in several of the human studies. However, one potentially important difference between conditioning procedures used

in DCS studies in animals and humans is that animal studies rely on only one CS (single cue conditioning), whereas human studies involve at least two CS (e.g., differential conditioning). It is possible that single cue and differential conditioning engage different mechanisms (lower- and higher-order processes, respectively) that are differentially sensitive to DCS.

Interpreting DCS's therapeutic effects during EBT: Implications from a two-level theory of fear conditioning

A dual-model theory of fear conditioning implies dissociable neural systems that may be affected differently by DCS and other therapeutic treatments. All lab-based DCS/fear conditioning experiments in humans have examined higher-order cognitive learning with negative results. The positive results in rodent studies suggest that DCS act on lower-level learning mechanisms—as the single-cue conditioning studies suggest. Hence, DCS may affect lower-order but not higher-order processes. Consequently, DCS may affect the implicit learning that takes place during EBT.

Both implicit and explicit cognitive processes are important in the etiology and treatment of anxiety disorders (58-60). Cognitive bias theories posit that vulnerability to anxiety stems from dysfunctional early, pre-attentive mechanisms that assess the threat value of stimuli; a later stage of attentional allocation is affected by the exaggerated output of the former mechanism and thus becomes excessively active (28,61). Similarly, conditioning models of fear and phobia place a strong emphasis on implicit learning in phobic- and trauma-related emotional memories (10,62). These models assume that a traumatic or frightening stimulus (i.e., an US) becomes associated with a benign stimulus (i.e., a CS) without formation of explicit memory. Subsequent exposure to the benign stimulus with minimum sensory input leads to a fast and automatic activation of the subcortical fear network, which occurs with little or no conscious awareness of the stimulus. One aim of EBT is to deactivate these automatic fear responses (58,60,63,64).

EBT attempts to correct dysfunctional cognition, emotion, and behaviors using various techniques such as flooding, systematic desensitization, and implosive therapies. These techniques are highly effective for the treatment of a range of anxiety disorders (65-69), but there is little agreement as to how they work (70,71). EBT can be traced back to Mowrer's two-factor theory of avoidance learning (72) and to classical conditioning principles positing that anxiety can be eliminated through extinction via direct experience with the unreinforced fear-producing CS acting via lower-order processes (63). Interpretations relying essentially on cognitive processes have also been proposed (71). More likely, EBT engages both implicit and explicit mechanisms. Current connectionist models consider that fear is represented in memory-based networks of associations or nodes that integrate perceptual, cognitive, and behavioral tendencies leading to implicit processing bias (59,70). These models are consistent with the view that therapeutic effects of EBT entail activation of implicit and explicit mechanisms leading to synaptic changes that alter how the fear network function and reduces processing bias (70). In fact, changes in lower-level automatic bias are postulated to be keys to treatment effectiveness (58). Supporting evidence has been recently reported. Specifically, changes in automatic fear association during the course of treatment predict symptom improvement in phobic (64) and in panic disorder (60) patients. These automatic fear associations may be the target of DCS's effects.

If DCS enhances EBT in phobias, why was no such facilitation observed in the study of individuals with non-clinical fear of spiders described above (51)? It is possible that DCS's effectiveness is restricted to severe phobic fears in DSM-diagnosed clinical samples; specifically, because fears are less severe and persistent in non-clinical phobias, EBT may reduce fear to a floor level so that further improvement cannot be gained using DCS (73). More

speculatively, the lower-order, automatic mechanisms on which DCS operates may play a more pivotal role in clinical phobias than in non-clinical fears. This could be caused by differences in the mode of fear acquisition. Because experiential/vicarious conditioning can lead to automatic CR, but verbal communication cannot (42), it is possible that clinical phobias result from the former type of conditioning, and non-clinical phobias from the latter. Preliminary evidence suggests that experiential/vicarious conditioning plays a greater role in clinical phobias than in common developmental fears in children (74). In addition, childhood phobias are far more likely to be associated with experiential or vicarious conditioning than with verbally-mediated information (75). For example, 41%, 19%, and 5% of children with spider phobia attribute their phobia to direct conditioning, observational learning, and verbal information, respectively (76).

Little is currently known about the effect of DCS on cognitive processes in general in humans. DCS's effects on explicit learning and memory, if any, appear to be very limited. For instance, DCS (50 mg) did not affect verbal and continuous performance tasks (77) and had no effect on verbal and non-verbal explicit cognitive tasks with non-emotional stimuli (78). Clearly, research needs to be extended to investigate its effects on implicit forms of learning and memory.

Alternative possibilities

At least three variables appear to play a key role in DCS's effectiveness: dose, the time of administration relative to extinction learning, and the number of extinction trials. First, the dose of DCS must be optimal; too little may not affect NMDA receptors and too much may reduce NMDA receptor function (79). However, a recent meta-analysis indicated that within the range used in human and animal studies, the dose of DCS was not significantly associated with its effect, including in non-patient studies (73).

Second, DCS should be given at a time that ensures that peak plasma levels are highest during post-extinction memory consolidation; according to rodent studies, this occurs one to two hours post-learning (80), but continues in waves lasting one to two days (81). In addition, extinction retention testing should take place during the post-consolidation period. These two requirements have been fulfilled in several non-patient studies. For instance, DCS was given shortly prior (one to two hours) to extinction learning or to EBT in all non-patient studies. DCS levels peak four to eight hours after oral administration, which corresponds to the peak period of post-extinction memory consolidation in these studies (73). Further, extinction testing took place 24-48 hours after extinction learning in several studies (52,56,57). Thus, the failure to find an augmenting effect for DCS on extinction in non-patients cannot be attributed to inadequate timing of drug ingestion or extinction testing.

Third, excessive numbers of extinction trials could reduce fear, so that such trials would not benefit from DCS augmentation (51,73). As noted above, several non-patient studies found that DCS had no beneficial effects despite significant recovery of fear during the extinction test phase (52,56). These results are inconsistent with the view that DCS does not affect extinction in humans due to inappropriately low fear levels.

While too many extinction trials can lead to too much extinction, too few trials may reactivate conditioned fear rather than extinguish it. In rodents, DCS facilitates retention of extinction only if there is successful extinction underway during extinction training (82-84). In fact, with too few extinction trials, DCS can lead to increased rather than decreased fear, perhaps because DCS facilitates memory reconsolidation (84) (but see (82)). Human studies usually rely on small numbers of extinction trials, but this does not prevent initiation of extinction, as shown by a progressive reduction in CR during extinction learning (52,56,57). It is unlikely that DCS's failure to facilitate extinction in humans is due to reduced number of extinction trials.

Nevertheless, there may be an optimal number of extinction trials required for DCS to operate, and future studies should investigate whether DCS's effectiveness depends on this variable.

Conclusion

Despite the effectiveness of DCS as an adjunct to EBT in clinical studies, the learning mechanisms on which DCS operates remain largely unknown. DCS's lack of efficacy on extinction in human lab-based experiments and as a treatment for subclinical fears provides important clues as to the potential learning mechanisms that it affects. More specifically, DCS may facilitate extinction and EBT specifically by modulating low-order, automatic learning. One implication of this view for psychological treatment is that DCS's effectiveness would be expected to be greater for EBT compared to cognitive therapy (e.g., cognitive restructuring).

A more general implication of a two-level theory of fear conditioning for translational research is that investigators should be mindful of important cross-species differences when conducting conditioning studies. First, the nature of conditioning (e.g., single cue vs. differential or contextual conditioning) may promote the use of lower-order or higher-order processes. In addition, noxious US must be perceived to be potentially lethal in animals. In human experiments, US are comparatively mildly aversive and pose no threat to survival. Mild US are less likely to activate automatic CRs than more intense US (36). Second, the nature of the cognitive processes involved in rodents (21) and humans are likely to be very different; volitional attention strongly influences CR in humans. Human research would more greatly benefit from basic research if more complex conditioning procedures engaging higher-level cognitive processes were used in animals (e.g., context conditioning, differential conditioning). Similarly, human research should devote greater efforts to developing robust conditioning experiments that are more impervious to cognition. Ideally, the best way to examine the effect of DCS on extinction in lab-based conditioning in humans would be to use fear-relevant CS, short CS-US intervals during acquisition, an intense US, and masked CS presentation during extinction.

Many practical questions remain unanswered concerning the mechanisms of action of DCS on conditioning processes, and the specific factors that affect DCS's effectiveness, such as the dose/time of treatment or the number of exposure/extinction trials. These questions can also be extended to other therapeutic interventions that may influence conditioning processes (acquisition, extinction, consolidation, reconsolidation) with potential implications for human mental health (e.g., beta-blockers, cortisone). Traditionally, these issues have been addressed via clinical trials, but clinical trials with patients are challenging, costly, and time-consuming. As an alternative, laboratory-based fear conditioning procedures present several advantages (e.g., low cost, easy-to-recruit non-clinical samples). Thus, fear conditioning in humans is an important step towards better characterizing drug effects on conditioning processes in order to inform clinical treatment. However, for the cross-fertilization of basic science and psychological science to benefit clinical science, the need to develop a better understanding of fear conditioning mechanisms and refine conditioning procedures in humans and in animals is key.

Acknowledgments

Financial support for this study was provided by the Intramural Research Program of the National Institute of Mental Health (NIMH). The author would like to thank Monique Ernst, Schmuël Lissek, Brian Cornwell, and Ruben Alvarez for comments on earlier versions of this manuscript, and Ioline Henter for her editorial assistance.

References

1. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, et al. Cognitive enhancers as adjuncts to psychotherapy: Use of D-Cycloserine in phobics to facilitate extinction. *Arch Gen Psychiatry* 2004;61:1136–1144. [PubMed: 15520361]
2. Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. *Arch Gen Psychiatry* 2006;63:298–304. [PubMed: 16520435]
3. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. *Biol Psychiatry* 1008;63:544–549. [PubMed: 18179785]
4. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. *Biol Psychiatry* 2007;62:835–838. [PubMed: 17588545]
5. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. *Am J Psychiatry* 2008;165:335–341. [PubMed: 18245177]
6. Otto MW. Learning and “unlearning” fears: preparedness, neural pathways, and patients. *Biol Psychiatry* 2002;52:917–920. [PubMed: 12437932]
7. Ledgerwood L, Richardson R, Cranney J. D-cycloserine and the facilitation of extinction of conditioned fear: consequences for reinstatement. *Behav Neurosci* 2004;118:505–513. [PubMed: 15174928]
8. Ledgerwood L, Richardson R, Cranney J. d-cycloserine facilitates extinction of learned fear: Effects on reacquisition and generalized extinction. *Biol Psychiatry* 2005;841–847. [PubMed: 15820704]
9. Walker DL, Ressler KJ, Lu KT, Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. *J Neurosci* 2002;2343–2351. [PubMed: 11896173]
10. Mineka S, Ohman A. Phobias and preparedness: the selective, automatic, and encapsulated nature of fear. *Biol Psychiatry* 2002;927–937. [PubMed: 12437934]
11. Razran G. Conditioning and perception. *Psychol Review* 1955;62:83–95.
12. Squire LR, Zola SM. Structure and function of declarative and nondeclarative memory systems. *Proc Natl Acad Sci U S A* 1996;93:13515–13522. [PubMed: 8942965]
13. Lovibond PF, Shanks DR. The role of awareness in Pavlovian conditioning: empirical evidence and theoretical implications. *J Exp Psychol Anim Behav Process* 2002;28:3–26. [PubMed: 11868231]
14. Dawson ME, Furedy JJ. The role of awareness in human differential autonomic classical conditioning: the necessary-gate hypothesis. *Psychophysiology* 1976;13:50–53. [PubMed: 1244630]
15. Phelps EA, LeDoux JE. Contributions of the amygdala to emotion processing: From animal models to human behavior. *Neuron* 2005;48:175–187. [PubMed: 16242399]
16. Romanski LM, LeDoux JE. Bilateral destruction of neocortical and perirhinal projection targets of the acoustic thalamus does not disrupt auditory fear conditioning. *Neuro Letters* 1992;142:228–232.
17. LeDoux JE. Emotion circuits in the brain. *Ann Rev Neurosci* 2000;23:155–184.
18. Romanski LM, LeDoux JE. Equipotentiality of thalamo-amygdala and thalamo-cortico-amygdala circuits in auditory fear conditioning. *J Neurosci* 1992;12:4501–4509. [PubMed: 1331362]
19. Lang PJ, Davis M. Chapter 1 Emotion, motivation, and the brain: Reflex foundations in animal and human research. *Prog Brain Res* 2006;156:3–29. [PubMed: 17015072]
20. Mineka S, Ohman A. Born to fear: non-associative vs associative factors in the etiology of phobias. *Behav Res Ther* 2002;40:173–184. [PubMed: 11814181]
21. Rescorla RA. Pavlovian conditioning: it’s not what you think. *American Psychologist* 1988;43:151–160. [PubMed: 3364852]
22. Teich AH, McCabe PM, Gentile CG, Jarrell TW, Winters RW, Liskowsky DR, et al. Role of auditory cortex in the acquisition of differential heart rate conditioning. *Physiol Behav* 1988;44:405–412. [PubMed: 3222363]
23. Kim JJ, Fanselow MS. Modality-specific retrograde amnesia of fear. *Science* 1992;256:675–677. [PubMed: 1585183]

24. Phillips RG, LeDoux JE. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. *Behav Neurosci* 1992;106:274–285.
25. Mandel IJ, Bridger WH. Is there classical conditioning without cognitive expectancy? *Psychophysiology* 1973;10:87–90. [PubMed: 4684237]
26. Schneider W, Shiffrin RM. Controlled and automatic human information processing I: detection, search and attention. *Psychol Rev* 1977;84:1–66.
27. Hamm AO, Weike AI. The neuropsychology of fear learning and fear regulation. *Int J Psychophysiol* 2005;57:5–14. [PubMed: 15935258]
28. Ohman A, Soares JFF. On the automatic nature of phobic fear: conditioned electrodermal responses to masked fear-relevant stimuli. *Journal of Abnormal Psychology* 1993;102:121–132. [PubMed: 8436688]
29. Esteves F, Bohlin G, Ohman A. Elicitation of skin conductance responses to backward masked emotional stimuli: Pictures of mutilated bodies. *Psychophysiology* 1993;30(Suppl1):s25.
30. Hamm AO, Weike AI, Schupp HT, Treig T, Dressel A, Kessler C. Affective blindsight: intact fear conditioning to a visual cue in a cortically blind patient. *Brain* 2003;126:267–275. [PubMed: 12538396]
31. Morris JS, Ohman A, Dolan RJ. A subcortical pathway to the right amygdala mediating ‘unseen’ fear. *Proc Natl Acad Sci U S A* 1999;96:1680–1685. [PubMed: 9990084]
32. Morris JS, Ohman A, Dolan RJ. Conscious and unconscious emotional learning in the human amygdala. *Nature* 1998;393:467–470. [PubMed: 9624001]
33. Grillon C. Associative learning deficits increase symptoms of anxiety in humans. *Biological Psychiatry* 2002;51:851–858. [PubMed: 12022957]
34. Squire LR, Zola SM. Structure and function of declarative and nondeclarative memory systems. *Proc Natl Acad Sci U S A* 1996;93:13515–13522. [PubMed: 8942965]
35. Bechara A, Tranel D, Damasio H, Adolphs R, Rockland C, Damasio AR. Double dissociation of conditioning and declarative knowledge relative to the amygdala and hippocampus in humans. *Science* 1995;269:1115–1118. [PubMed: 7652558]
36. Schell A, Dawson M, Marinkovic K. Effects of potentially phobic conditioned stimuli on retention, reconditioning, and extinction of the conditioned skin conductance response. *Psychophysiology* 1991;28:140–153. [PubMed: 1946880]
37. Bridger WH, Mandel IJ. A comparison of the GSR fear responses produced by threat and electric shock. *Journal Psychiatry Research* 1964;2:31–40.
38. Rachman S. The conditioning of fear-acquisition: a critical examination. *Behav Res Ther* 1977;15:375–387. [PubMed: 612338]
39. Kavaliers M, Choleris E, Colwell DD. Learning from others to cope with biting flies: social learning of fear-induced conditioned analgesia and active avoidance. *Behav Neurosci* 2001;115:661–674.
40. John ER, Chesler P, Bartlett F, Victor I. Observation learning in cats. *Science* 1968;159:1489–1491. [PubMed: 5732493]
41. Mineka S, Davidson M, Cook M, Keir R. Observational conditioning of snake fear in rhesus monkeys. *J Abn Psychol* 1984;93:355–372.
42. Olsson A, Phelps EA. Learned fear of “unseen” faces after Pavlovian, observational, and instructed fear. *Psychol Sci* 2004;15:822–828. [PubMed: 15563327]
43. Grillon C, Ameli R, Woods SW, Merikangas K, Davis M. Fear-potentiated startle in humans: effects of anticipatory anxiety on the acoustic blink reflex. *Psychophysiology* 1991;28:588–595. [PubMed: 1758934]
44. Field AP, Argyris NG, Knowles KA. Who’s afraid of the big bad wolf: a prospective paradigm to test Rachman’s indirect pathways in children. *Behaviour Research and Therapy* 2001;39:1259–1276. [PubMed: 11686263]
45. Ollendick TH, King NJ. Origins of childhood fears: an evaluation of Rachman’s theory of fear acquisition. *Behaviour Research and Therapy* 1991;29:117–123. [PubMed: 2021373]
46. Falls WA, Miserendino MJD, Davis M. Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. *J Neurosci* 1992;12:854–863. [PubMed: 1347562]

47. Fanselow MS, LeDoux JE. Why we think plasticity underlying pavlovian fear conditioning occurs in the basolateral amygdala. *Neuron* 1999;23:229–132. [PubMed: 10399930]
48. Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. *Biol Psychiatry* 2006;60:369–375. [PubMed: 16919524]
49. Parnas AS, Weber M, Richardson R. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. *Neurobiology of learning and memory* 2005;83:224–231. [PubMed: 15820858]
50. Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, et al. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. *Int Clin Psychopharmacol* 2007;22:230–237. [PubMed: 17519647]
51. Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R. A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. *J Psychiatr Res* 2007;41:466–471. [PubMed: 16828803]
52. Guastella AJ, Lovibond PF, Dadds MR, Mitchell P, Richardson R. A randomized controlled trial of the effect of d-cycloserine on extinction and fear conditioning in humans. *Behav Res Ther* 2007;45:663–72. [PubMed: 16962066]
53. Kalisch R, Holt B, Petrovic P, De Martino B, Klöppel S, Büchel C, et al. The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans. *Cerebral Cortex* 2009;19:187–196. [PubMed: 18477687]
54. Hamm AO, Vaitl D. Affective learning: awareness and aversion. *Psychophysiology* 1996;33:698–710. [PubMed: 8961792]
55. Grillon C, Baas JM. A review of the modulation of startle by affective states and its application to psychiatry. *Clinical Neurophysiology* 2003;114:1557–1579. [PubMed: 12948786]
56. Baas JMP, Klumpers F, Kenemans JL, Grillon C, Olivier B, Denys D. The effects of Δ^9 -THC and d-cycloserine on extinction of conditioned fear in humans. submitted
57. Grillon C. No effect of D-cycloserine on extinction and fear conditioning in humans: implication for future studies. in preparation
58. Beck AT, Clark DA. An information processing model of anxiety: automatic and strategic processes. *Behav Res Ther* 1997;35:49–58. [PubMed: 9009043]
59. Foa EB, Kozak MJ. Emotional processing of fear: exposure to corrective information. *Psychological Bulletin* 1986;99:20–35. [PubMed: 2871574]
60. Teachman BA, Marker CD, Smith-Janik SB. Automatic associations and panic disorder: trajectories of change over the course of treatment. *Journal of Consulting and Clinical Psychology* 2008;76:988–1002. [PubMed: 19045967]
61. Mogg K, Bradley BP. A cognitive-motivational analysis of anxiety. *Behav Res Ther* 1998;36:809–848. [PubMed: 9701859]
62. LeDoux, J. *The Emotional Brain*. New York: Simon & Schuter; 1996.
63. Levis, DJ. The case for a return to a two-factor theory of avoidance: The failure of the non-fear interpretation. In: Klein, SB.; Mowrer, RR., editors. *Contemporary learning theories: Pavlovian conditioning and the status of traditional learning theory*. Hillsdale, NJ: Erlbaum; 1989. p. 227–77.
64. Teachman BA, Woody SR. Automatic processing in spider phobia: implicit fear associations over the course of treatment. *Journal of Abnormal Psychology* 2003;112:100–109. [PubMed: 12653418]
65. Feske U, Chambless DL. Cognitive behavioral versus exposure only treatment for social phobia: A meta-analysis. *Behavior Therapy* 1995;26:695–720.
66. Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. *Br J Psychiatry* 2007;188:305–312. [PubMed: 16582055]
67. Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. *Journal of consulting and clinical psychology* 1997;65:44–52. [PubMed: 9103733]
68. Foa EB, Hembree EA, Cahill SP, Rauch SAM, Riggs DS, Feeny NC, et al. Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring: outcome at academic and community clinics. *Journal of consulting and clinical psychology* 2005;73:953–964. [PubMed: 16287395]

69. Ost LG, Svensson L, Hellstrom K, Lindwall R. One-Session treatment of specific phobias in youths: a randomized clinical trial. *J Consult Clin Psychol* 2001;69:814–824. [PubMed: 11680558]
70. Tryon WW. Possible mechanisms for why desensitization and exposure therapy work. *Clinical Psychology Review* 2005;25:67–95. [PubMed: 15596081]
71. Hofmann SG. Cognitive processes during fear acquisition and extinction in animals and humans: implications for exposure therapy of anxiety disorders. *Clinical Psychology Rev* 2008;28:199–210.
72. Mowrer OH. A stimulus-response analysis of anxiety and its role as a reinforcing agent. *Psychol Rev* 1939;46:553–565.
73. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. *Biol Psychiatry* 2008;63:1118–1126. [PubMed: 18313643]
74. King NJ, Clowes-Hollins V, Ollendick TH. The etiology of childhood dog phobia. *Behav Res Ther* 1997;35:77. [PubMed: 9009047]
75. King NJ, Eleonora G, Ollendick TH. Etiology of childhood phobias: current status of Rachman's three pathways theory. *Behav Res Ther* 1998;36:297–309. [PubMed: 9642849]
76. Merkelbach H, Muris P, Schouten E. Pathways to fear in spider phobic children. *Behav Res Ther* 1996;34:935–938. [PubMed: 8990545]
77. D'Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, et al. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. *Biol Psychiatry* 2000;47:450–462. [PubMed: 10704956]
78. Otto MW, Basden SL, McHugh RK, Kantak KM, Deckersbach T, Cather C, et al. Effects of D-cycloserine administration on weekly nonemotional memory tasks in healthy participants. *Psychosom* 2009;78:49–54.
79. Emmett MR, Mick SJ, Cler JA, Rao TS, Iyengar S, Wood PL. Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. *Neuropharmacology* 1991;30:1167–1171. [PubMed: 1663594]
80. Scavio MJ, Clift PS, Wills JC. Posttraining effects of amphetamine, chlorpromazine, ketamine, and scopolamine on the acquisition and extinction of the rabbit's conditioned nictitating membrane response. *Behav Neurosci* 1992;106:900–908. [PubMed: 1472293]
81. Santini E, Muller RU, Quirk GJ. Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. *J Neurosci* 2001;21:9009–9017. [PubMed: 11698611]
82. Bouton ME, Vurbic D, Woods AM. D-cycloserine facilitates context-specific fear extinction learning. *Neurobiol Learn Mem* 2008;90:504–510. [PubMed: 18672079]
83. Weber M, Hart J, Richardson R. Effects of D-cycloserine on extinction of learned fear to an olfactory cue. *Neurobiol Learn Mem* 2007;87:476–482. [PubMed: 17275356]
84. Lee JL, Milton AL, Everitt BJ. Reconsolidation and extinction of conditioned fear: inhibition and potentiation. *J Neurosci* 2006;26:10051–10056. [PubMed: 17005868]